Markets›PBM

Psyence Biomedical Ltd.

PBM · NASDAQ-CM
5.67
+0.11 (+1.89%)
Last price from Nasdaq, delayed

Key statistics

Previous close5.56
52-week range1.92 to 28.12
Volume48.3K
Average volume (3 months)93.2K
1-year price change-71.59%
Market value21.61M
Beta (1 year)1.69
Dividend yieldNone

Company figures come from SEC filings through the quarter ending Sep 30, 2025. All statistics

About Psyence Biomedical Ltd.

Full profile

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Industry: Pharmaceutical Preparations · Employees: 12 · Headquarters: TORONTO

For learning only, not investment advice. Chart by TradingView. How to read a stock quote.